Zevra Therapeutics Publishes Four-Year MIPLYFFA Real-World NPC Data
BOSTON, Aug. 3, 2026 Zevra Therapeutics, Inc. announced the publication of four-year real-world safety and effectiveness data evaluating MIPLYFFA®...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
BOSTON, Aug. 3, 2026 Zevra Therapeutics, Inc. announced the publication of four-year real-world safety and effectiveness data evaluating MIPLYFFA®...
CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
